Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

Virus-Like Particles Expressing Toxoplasma gondii Rhoptry Protein 18 Induces Better Protection Than Rhoptry Protein 4 against T. gondii Infection

  • Kang, Hae-Ji (Department of Biomedical Science, Graduate School, Kyung Hee University) ;
  • Lee, Su-Hwa (Department of Biomedical Science, Graduate School, Kyung Hee University) ;
  • Chu, Ki-Back (Department of Biomedical Science, Graduate School, Kyung Hee University) ;
  • Lee, Dong-Hun (Department of Biomedical Science, Graduate School, Kyung Hee University) ;
  • Quan, Fu-Shi (Department of Medical Zoology, Kyung Hee University School of Medicine)
  • Received : 2018.07.27
  • Accepted : 2018.09.20
  • Published : 2018.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Toxoplasma gondii is a ubiquitous protozoan parasite responsible for causing toxoplasmosis. Preventive measures for toxoplasmosis are currently lacking and as such, development of novel vaccines are of urgent need. In this study, we generated 2 virus-like particles (VLPs) vaccines expressing T. gondii rhoptry protein 4 (ROP4) or rhoptry protein 18 (ROP18) using influenza matrix protein (M1) as a core protein. Mice were intranasally immunized with VLPs vaccines and after the last immunization, mice were challenged with ME49 cysts. Protective efficacy was assessed and compared by determining serum antibody responses, body weight changes and the reduction of cyst counts in the brain. ROP18 VLPs-immunized mice induced greater levels of IgG and IgA antibody responses than those immunized with ROP4 VLPs. ROP18 VLPs immunization significantly reduced body weight loss and the number of brain cysts in mice compared to ROP4 VLPs post-challenge. These results indicate that T. gondii ROP18 VLPs elicited better protective efficacy than ROP4 VLPs, providing important insight into vaccine design strategy.

Keywords

References

  1. Parlog A, Schluter D, Dunay IR. Toxoplasma gondii-induced neuronal alterations. Parasite Immunol 2015; 37: 159-170. https://doi.org/10.1111/pim.12157
  2. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000; 30: 1217-1258. https://doi.org/10.1016/S0020-7519(00)00124-7
  3. Jones JL, Parise ME, Fiore AE. Neglected parasitic infections in the United States: toxoplasmosis. Am J Trop Med Hyg 2014; 90: 794-799. https://doi.org/10.4269/ajtmh.13-0722
  4. Goldstein EJC, Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 2008; 47: 554-566. https://doi.org/10.1086/590149
  5. Liu Q, Singla LD, Zhou H. Vaccines against Toxoplasma gondii: status, challenges and future directions. Hum Vaccin Immunother 2012; 8: 1305-1308. https://doi.org/10.4161/hv.21006
  6. Yuan ZG, Zhang XX, Lin RQ, Petersen E, He S, Yu M, He XH, Zhou DH, He Y, Li HX, Liao M, Zhu XQ. Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding Toxoplasma gondii ROP18. Vaccine 2011; 29: 6614-6619. https://doi.org/10.1016/j.vaccine.2011.06.110
  7. Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res 2009; 143: 140-146. https://doi.org/10.1016/j.virusres.2009.04.005
  8. Lee DH, Lee SH, Kim AR, Quan FS. Virus-like nanoparticle vaccine confers protection against Toxoplasma gondii. PLoS One 2016; 11: e0161231. https://doi.org/10.1371/journal.pone.0161231
  9. Lee SH, Kim AR, Lee DH, Rubino I, Choi HJ, Quan FS. Protection induced by virus-like particles containing Toxoplasma gondii microneme protein 8 against highly virulent RH strain of Toxoplasma gondii infection. PLoS One 2017; 12: e0175644. https://doi.org/10.1371/journal.pone.0175644
  10. Lee SH, Kang HJ, Lee DH, Kang SM, Quan FS. Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection. Vaccine 2018; 36: 5692-5700. https://doi.org/10.1016/j.vaccine.2018.08.016
  11. Lee SH, Lee DH, Piao Y, Moon EK, Quan FS. Influenza M1 viruslike particles consisting of Toxoplasma gondii rhoptry protein 4. Korean J Parasitol 2017; 55: 143-148. https://doi.org/10.3347/kjp.2017.55.2.143
  12. Joyce BR, Queener SF, Wek RC, Sullivan WJ Jr. Phosphorylation of eukaryotic initiation factor-2{alpha} promotes the extracellular survival of obligate intracellular parasite Toxoplasma gondii. Proc Natl Acad Sci USA 2010; 107: 17200-17205. https://doi.org/10.1073/pnas.1007610107
  13. Wang PY, Yuan ZG, Petersen E, Li J, Zhang XX, Li XZ, Li HX, Lv ZC, Cheng T, Ren D, Yang GL, Lin RQ, Zhu XQ. Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice. Clin Vaccine Immunol 2012; 19: 1916-1920. https://doi.org/10.1128/CVI.00397-12
  14. Fang R, Feng H, Nie H, Wang L, Tu P, Song Q, Zhou Y, Zhao J. Construction and immunogenicity of pseudotype baculovirus expressing Toxoplasma gondii SAG1 protein in BALB/c mice model. Vaccine 2010; 28: 1803-1807. https://doi.org/10.1016/j.vaccine.2009.12.005
  15. Choi HJ, Yoo DG, Bondy BJ, Quan FS, Compans RW, Kang SM, Prausnitz MR. Stability of influenza vaccine coated onto microneedles. Biomaterials 2012; 33: 3756-3769. https://doi.org/10.1016/j.biomaterials.2012.01.054
  16. Wek RC, Cavener DR. Translational control and the unfolded protein response. Antioxid Redox Signal 2007; 9: 2357-2371. https://doi.org/10.1089/ars.2007.1764
  17. Fentress SJ, Sibley LD. The secreted kinase ROP18 defends Toxoplasma's border. Bioessays 2011; 33: 693-700. https://doi.org/10.1002/bies.201100054
  18. Dorfmeier CL, Shen S, Tzvetkov EP, McGettigan JP. Reinvestigating the role of IgM in rabies virus postexposure vaccination. J Virol 2013; 87: 9217-9222. https://doi.org/10.1128/JVI.00995-13
  19. Racine R, Winslow GM. IgM in microbial infections: taken for granted? Immunol Lett 2009; 125: 79-85. https://doi.org/10.1016/j.imlet.2009.06.003
  20. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM, Pushko P, Tumpey TM. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009; 83: 5726-5734. https://doi.org/10.1128/JVI.00207-09

Cited by

  1. Previous Infection with Plasmodium berghei Confers Resistance to Toxoplasma gondii Infection in Mice vol.57, pp.2, 2018, https://doi.org/10.3347/kjp.2019.57.2.93
  2. Influenza Virus-Like Particles Presenting both Toxoplasma gondii ROP4 and ROP13 Enhance Protection against T. gondii Infection vol.11, pp.7, 2018, https://doi.org/10.3390/pharmaceutics11070342
  3. Virus-like particles containing multiple antigenic proteins of Toxoplasma gondii induce memory T cell and B cell responses vol.14, pp.8, 2019, https://doi.org/10.1371/journal.pone.0220865
  4. Evaluation of CpG-ODN-Adjuvanted Toxoplasma gondii Virus-Like Particle Vaccine upon One, Two, and Three Immunizations vol.12, pp.10, 2018, https://doi.org/10.3390/pharmaceutics12100989
  5. Protective immunity induced by CpG ODN‐adjuvanted virus‐like particles containing Toxoplasma gondii proteins vol.43, pp.1, 2018, https://doi.org/10.1111/pim.12799